Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising.
- Onco-Innovations is developing ONC010(TM), a nanoparticle-encapsulated PNKP inhibitor designed to target DNA repair pathways involved in cancer survival and treatment resistance.
- The company is positioning itself as a leader in the emerging PNKP inhibitor class, a segment of the broader DNA Damage Response therapy market that is distinct from established PARP inhibitor therapies.
- Five patents protect the company’s PNKP inhibitor technology, nanoparticle delivery platform and related applications, supporting its intellectual property position as development advances.
- Through its wholly owned subsidiary Inka Health, Onco-Innovations has integrated the SynoGraph(TM) causal AI platform to support patient stratification, clinical trial design and oncology evidence generation.
- Ongoing CMC, IND-enabling and preclinical development activities are intended to support advancement of ONC010 toward planned first-in-human clinical studies.
Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) is a clinical-stage oncology company focused on advancing a new class of DNA Damage Response (“DDR”) therapies and developing artificial intelligence-driven precision oncology solutions. The company is leading the development of Polynucleotide Kinase Phosphatase (“PNKP”) inhibitors, an emerging category of DDR therapeutics designed to target DNA repair pathways involved in cancer survival and resistance. Through its dual-platform approach, Onco-Innovations combines proprietary drug development with AI-enabled technologies intended to support oncology research, clinical development, patient stratification and evidence generation.
The company’s strategy is centered on building a scalable oncology platform supported by proprietary intellectual property, strategic collaborations and integrated development capabilities. In recent years, Onco-Innovations has expanded its operational footprint through acquisitions, research partnerships…
NOTE TO INVESTORS: The latest news and updates relating to ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN
